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Applying new technologies for diagnosing sexually
transmitted infections in resource-poor settings
Rosanna W Peeling
INTRODUCTION
Bacterial sexually transmitted infections (STI)
syphilis, chlamydia and gonorrhoea impose
a disproportionate disease burden on women and
children in the developing world. Diagnostic testing
is particularly critical for the detection of STI, as
most infected individuals have few or no symp-
toms. Genital chlamydial and gonococcal infections
in women can lead to chronic pelvic pain, ectopic
pregnancy or tubal infertility. Syphilis in pregnancy
can result in stillbirth, spontaneous abortion or
babies with congenital syphilis, 50% of whom may
die in the ﬁrst year of life. Bacterial STI are curable
and treatment is affordable, but sensitive diagnostic
tests are required for early detection to guide
treatment to prevent the development of repro-
ductive sequelae and adverse outcomes of preg-
nancy, and to interrupt onward transmission.
In resource-poor settings, laboratory services for
STI are either not available, or where limited
services are available, patients may not be able to
pay for or physically access these services. In sub-
Saharan Africa, only 30% of pregnant women with
syphilis are screened and treated, even though
universal screening of pregnant women for syphilis
is the recommended policy in many countries. The
major obstacle is the lack of access to laboratories
that can offer screening as women often have to
travel long distances to reach a hospital or clinic
with such services. Many women also fail to return
for test results and treatment after the initial visit.
In recent years, rapid tests have made it possible to
increase access to STI testing to all levels of the
healthcare system. A mathematical model esti-
mated that a test for syphilis that requires no
laboratory infrastructure could save more than
201 000 lives and avert 215 000 stillbirths per year
worldwide. A similar test could save approximately
four million disability-adjusted life-years, avert
more than 16.5 million incident gonorrhoea and
chlamydial infections and prevent more than
212 000 HIV infections per year.1
This article examines new technologies available
on a 2e4 year horizon and how they may be
applied to the diagnosis of STI in resource-poor
settings to reduce the burden of STI (table 1).
NEW TECHNOLOGIES
Rapid tests
Immunochromatographic tests (ICT) that can use
ﬁngerprick blood specimens are commercially
available for HIVand syphilis. They fulﬁl the WHO
ASSURED criteria of being affordable, sensitive,
speciﬁc, user-friendly requiring minimal trained
personnel, rapid and robust (no special storage
conditions and can give results in 15e20 min),
equipment free and deliverable to those who need
them.2 These rapid tests have improved the effec-
tiveness of prevention of mother to child trans-
mission programmes for HIV and syphilis because
of shorter patient wait times, ease of use, lower
cost and obviating the need for follow-up and
treatment. It is now possible to develop a compre-
hensive rapid diagnostic package for prenatal care
by combining them with rapid tests for anaemia or
malaria. Rapid tests are also useful in reducing the
reservoir of transmission for STI if used for
screening for high-risk populations in outreach
settings.
On the horizon are lateral ﬂow ICT that are
designed for duplex (HIV and syphilis) or multiplex
testing (HIV, syphilis and hepatitis B or C) using
a single ﬁngerprick blood sample. Several of these
tests are already in clinical trials. Details of a rapid
test that can detect both non-treponemal and
treponemal antibodies using patented dual path
technology have recently been published.3
To improve test sensitivity, a number of simple
inexpensive optical or chemiluminescent readers are
now commercially available for use with ICT. The
use of these readers removes observer bias,
improves sensitivity and allows for quantitation
such as for non-treponemal titres. Several compa-
nies are developing oral ﬂuid tests for syphilis alone
or in a duplex test with HIV.
While ICT can detect antibodies with high
sensitivity, they tend to be less sensitive for the
detection of antigen. Most rapid tests for the
detection of genital chlamydial and gonococcal
infections have sensitivities of only 50e70%
compared with nucleic acid ampliﬁed tests. A
recent publication reported a rapid test that detects
the chlamydial lipopolysaccharide with a sensi-
tivity of 84% and a speciﬁcity of 99% in women
compared with urine PCR.4 Although promising,
its utility in resource-poor settings remains unclear
until independent evaluations of its performance
are carried out.
Microfluidic assays
Microﬂuidic assays that can detect multiple analytes
from a single specimen or can reproduce all the
performance characteristics of an immunoassay
have been developed and applied to HIV and syph-
ilis.5 The assays have few moving parts and the
chips cost pennies instead of dollars, making them
suitable for resource-poor settings. The results can
be read with a small battery-powered device. Some
of these assays are now in trials in Africa.
Molecular tests
Recent developments in integrated nucleic acid
ampliﬁcation platforms have given rise to sensitive,
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speciﬁc, user-friendly, sample-in, answer-out diagnostic tools for
infectious diseases. These technologies are promising for the
multiplex detection of pathogens associated with the major STI
syndromes. The GeneXpert assay for tuberculosis has a reported
sensitivity of 95% and a speciﬁcity of 98% against culture and
PCR, and can give a result for both the detection of tuberculosis
and rifampicin resistance in under 2 h.6 Tests for chlamydia and
gonorrhoea using this platform will soon be commercially
available. The machine allows random access, which makes it
more cost-effective if the equipment can be used for different
infectious diseases. As donor agencies are planning to purchase
this equipment for tuberculosis control programmes, STI
programmes may be able to beneﬁt from these investments to
make this an affordable technology for resource-poor settings for
the diagnosis of STI.
There are a few promising isothermal nucleic acid ampliﬁca-
tion technologies that are rapid and simple to perform. The
recombinase polymerase ampliﬁcation is a 15-min assay that can
achieve the same sensitivity and speciﬁcity as current molecular
assays by coupling isothermal recombinase-driven primer
targeting of template material with strand-displacement DNA
synthesis. It achieves exponential ampliﬁcation with no need for
pretreatment of sample DNA.7 The results can be read on
a ﬂuorimeter or in a lateral ﬂow strip. An integrated platform
for rolling circle ampliﬁcation and circle-to-circle ampliﬁcation
and subsequent electrophoretic detection of a speciﬁc gene on
a poly(methyl methacrylate) microchip has been developed.8
Rolling circle ampliﬁcation and circle-to-circle ampliﬁcation are
carried out at 378C in the sample well of the microchip, and
provide a sensitive, fast, high-throughput and reproducible
method for signal ampliﬁcation. These are being developed for
the detection of infectious disease, including chlamydia and
gonorrhoea.
Rapid advances in sequencing technologies, such as nanopore
technology, have made it possible to conduct genome-wide scans
rapidly and at a relatively low cost. These technologies can be
applied to the detection of gonococcal resistance.
IMPLEMENTING NEW TECHNOLOGIES IN RESOURCE-POOR
SETTINGS
Having new technologies is only one side of the coin.9 For the
best diagnostics to have the desired impact, they must reach
those who are in greatest need. The 2004 Health Development
Report cited lack of access and unaffordability as two major
reasons why services fail.10 Access to high quality diagnostics
depends on a functioning healthcare infrastructure with health
workers trained and motivated to do the work. In resource-poor
settings, limited laboratory facilities, few skilled laboratory
personnel, unreliable supply chain management of drugs, diag-
nostics and other commodities, disjointed health information
systems, competing vertical ‘global health’ initiatives, scarce
drug supply and weak policy all contribute to the problems of
effective implementation.
To address these problems, investments in technological
innovation must be balanced with investments to strengthen
health systems.11 Quality assurance programmes, developed
primarily for laboratories, must be adapted for point-of-care
testing. For individuals infected with STI, stigma and social
norms add another layer onto physical and ﬁnancial barriers to
accessing diagnostic services. Implementation research on the
introduction of rapid syphilis tests in China showed that those
who are at highest risk of syphilis and have the largest number
of clients are least likely to accept free screening and treatment
for syphilis. More needs to be done to increase the uptake of
screening for HIV and STI in high-risk populations.
In a recent project to introduce rapid syphilis tests to increase
access to syphilis screening in prenatal and high-risk populations
in seven countries in Africa, Asia and the Americas, a framework
and a critical path were developed for test introduction to ensure
sustainable adoption (ﬁgure 1). The framework uses a same day
testing and treatment strategy and starts with political
commitment, policy and planning followed by technical guid-
ance, quality assurance and monitoring and evaluation. Political
commitment for syphilis screening came from the global
strategy for the prevention and control of STI, developed by the
WHO for 2006e15, which includes expanding access to STI care
and elimination of congenital syphilis. PAHO and Unicef have
advocated for a syphilis-free and an HIV-free generation.
To facilitate more effective implementation, it would be useful
to develop a tool kit for test introduction, which may consist of:
a template for advocacy; a policy platform to facilitate the
translation of research evidence into policy and practice;
a programme managers’ guide; a mathematical model to estimate
the impact and cost-effectiveness of antenatal screening for
Table 1 Diagnostics for major STI syndromes
Major STI syndromes Pathogens Existing technologies New technologies
Urethral discharge Chlamydia trachomatis
Neisseria gonorrhoeae
Antigen detection: enzyme immunoassay
or rapid antigen test
NAAT
Rapid multiplex NAATs:
GeneXpert,
Recombinase Polymerase Amplification,
Rolling Circle Amplification
and other rapid NAATs
Vaginal discharge Chlamydia trachomatis,
Neisseria gonorrhoeae
Trichomonas vaginalis
Bacterial vaginosis
Antigen detection: enzyme immunoassay
or rapid antigen test
NAAT
Microscopy
Rapid multiplex NAATs:
GeneXpert,
Recombinase polymerase amplification,
Rolling circle amplification
and other rapid NAATs
Genital ulcer Haemophilus ducreyi Culture If ulcer present: Rapid multiplex NAAT
Herpes simplex type 2 Serology, NAAT Serology: Rapid multiplex testing, or in combination with
HIV, syphilis and/or Hepatitis B or C
Treponema pallidum Dark field microscopy
Serology:
Non-treponemal tests: RPR/VDRL
Treponemal tests:
TPHA/TPPA/Rapid tests
Serology
Rapid duplex non-treponemal and treponemal tests
Rapid treponemal tests using oral fluid
Genital warts Human papilloma virus Rapid antigen detection
NAAT
Rapid NAAT
NAAT, nucleic acid amplified test; RPR, rapid plasma reagin; STI, sexually transmitted infection; TPHA, Treponema pallidum haemagglutination assay; TPPA, Treponema pallidum Particle
Agglutination assay; VDRL, Venereal Disease Research Laboratory.
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syphilis; a data collection tool to identify barriers to screening;
testing and treatment algorithms; procurement advice and
guidance on supply chain and stock management to prevent
stock-outs; training and training-of-trainers packages; quality
assurance/quality control systems to ensure the quality of
tests and of testing; monitoring and evaluation tools for moni-
toring the effectiveness of training and sustainability of test
introduction.
Accessible tests have the potential to empower health providers,
including midwives and nurses at all sites, as they can offer
a better service to their patients by screening at their ﬁrst visit and
giving their results immediately, rather than having to return for
them. These tests can strengthen health systems by simplifying
services and facilitating the integration of HIV and STI services.
CONCLUSION
Recent investments in rapid ampliﬁcation and detection tech-
nologies will result in accessible and affordable tests for the
diagnosis of STI in resource-poor settings in the next few years.
Among them are duplex antigen tests that can be used for STI
syndromes and rapid lateral ﬂow tests that can be used with oral
ﬂuid. Molecular tests providing sample-in, answer-out conve-
nience or simple isothermal nucleic acid ampliﬁcation technol-
ogies that can give an answer in 15e60 min with no special
equipment will provide unprecedented test performance with
ease of use. Financing mechanisms and implementation issues in
resource-poor settings are important areas to address to ensure
the full impact of new technologies.
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